GlassScriptPhysician profile
Kesavan Shan
NPI 1619080843
$8,895.78
in general payments reported to CMS, 2019-2025
43 companies · $1,551 in 2025
The $1,551 reported for 2025 was more than what 79% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $848 · 2020: $292 · 2021: $871 · 2022: $1,607 · 2023: $1,959 · 2024: $1,767 · 2025: $1,551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,276.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,268.77 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $919.03 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $706.93 | 2021-2025 | Verquvo, Capvaxive |
| Abbott Laboratories | $647.41 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Navitor, Supera |
| Amgen INC. | $622.54 | 2019-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $485.12 | 2019-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $482.54 | 2019-2025 | Farxiga |
| Pfizer INC. | $434.96 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $355.87 | 2019-2025 | Eliquis, Camzyos |
| Medtronic, INC. | $344.57 | 2023-2025 | Corevalve Evolut R |
| Boehringer Ingelheim Pharmaceuticals, INC. | $289.39 | 2021-2024 | Jardiance |
| Impulse Dynamics (USA) INC. | $265.81 | 2022-2024 | Optimizer, Optimizer |
| Boston Scientific Corporation | $232.01 | 2019-2025 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor, Bodyguardian |
| Amarin Pharma, INC. | $157.39 | 2019-2022 | |
| Novo Nordisk INC | $149.74 | 2022-2025 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $138.03 | 2023-2024 | Inpefa |
| Cvrx, INC. | $119.80 | 2022-2024 | Barostim Neo System |
| Regeneron Healthcare Solutions, INC. | $114.79 | 2019-2024 | Evkeeza, Praluent |
| Biosense Webster, INC. | $113.58 | 2025 | Carto 3 |
| Heartflow, INC. | $105.62 | 2019-2025 | |
| Pulmonx Corporation | $91.69 | 2024 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Bayer Healthcare Pharmaceuticals INC. | $80.00 | 2021-2022 | |
| Abiomed | $73.32 | 2025 | |
| Irhythm Technologies, INC. | $73.03 | 2022-2023 | Zio Xt Patch |
| Altathera Pharmaceuticals LLC | $70.46 | 2023 | Sotalol Hydrochloride |
| Actelion Pharmaceuticals US, INC. | $64.40 | 2019-2023 | Opsumit, Uptravi |
| Esperion Therapeutics, INC. | $56.02 | 2021-2023 | Nexletol |
| Azurity Pharmaceuticals, INC. | $43.87 | 2024 | Edarbi |
| Kiniksa Pharmaceuticals International, Plc | $43.66 | 2024 | Arcalyst |
| Astellas Pharma US INC | $42.60 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $36.98 | 2022 | |
| Cagent Vascular INC | $36.61 | 2025 | Serrantor |
| Biotronik INC. | $31.65 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $25.41 | 2021-2022 | |
| Edwards Lifesciences Corporation | $23.50 | 2022 | |
| Alnylam Pharmaceuticals INC. | $23.40 | 2023 | Onpattro |
| Inspire Medical Systems, INC. | $22.93 | 2024 | Inspire |
| Baxter Healthcare | $20.91 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Kiniksa Pharmaceuticals, LTD. | $20.81 | 2023 | Arcalyst |
| Medtronic USA, INC. | $16.74 | 2020 | |
| Agepha Pharma Fz LLC | $16.42 | 2024 | Lodoco |
| Becton, Dickinson and Company | $14.12 | 2024 | Rotarexs 6 F X 135 Cm |
| Cardiva Medical, INC. | $13.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kesavan Shan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.